Spectrum Pharmaceuticals, a biotechnology company with a primary focus in hematology and oncology, has appointed Joseph Turgeon, previously senior vice president and COO, as president and COO, replacing Ken Keller. Thomas Riga, previously vice president, corporate accounts, will become the senior vice president, COO.
Turgeon joined Spectrum in October 2012 and has over 30 years of pharmaceutical sales experience. Prior to joining the Spectrum, he spent 22 years at Amgen as VP of sales. Riga has over 15 years of pharmaceutical sales and management experience and has worked at Amgen, EliLilly, and Dendreon.
Source: Spectrum Pharmaceuticals